Partex Announces Strategic Collaboration with Shanghai Ark Biopharmaceutical forPartnership and Out-Licensing of AK0707

Partnership aims to expand therapeutic potential of proprietary autotaxin inhibitor through AI-driven approach

Frankfurt, Germany – Date – Partex, a leader in AI-driven pharmaceutical innovation, is pleased to announce a strategic collaboration with Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”), a leading Chinese biopharmaceutical company, to out-license ArkBio’s proprietary autotaxin inhibitor, AK-0707. Under this partnership, Partex will leverage its cutting-edge AI technology to identify new indications and potential partners for AK0707, furthering its therapeutic potential beyond the current development in idiopathic pulmonary fibrosis (IPF). On behalf of ArkBio, Partex will then reach out and find the right partner and negotiate the terms for the asset.

The product, AK0707, has shown promise in the treatment of IPF, a debilitating lung disease, but recent research has also indicated that autotaxin inhibitors may hold therapeutic value in treating other serious conditions, including progressive-pulmonary fibrosis (PPF), interstitial lung disease (ILD), systemic sclerosis, metabolic associated steatohepatitis (MASH), neuropathic pain, and even pancreatic cancer.

Partex will apply its proprietary AI-powered platform, Asset42, to explore the broad therapeutic potential of AK0707, identifying new indications and potential industry partners that could benefit from the compound.

“We are excited to partner with ArkBio to unlock the full potential of AK0707,” said Dr. Frank Grams, Chief Commercial Officer, Partex. “By utilizing our AI technology, we believe we can significantly accelerate the process of expanding the compound’s indication space and connecting it with the right pharmaceutical partners. This partnership is a great example of how AI can drive innovation in drug development and licensing.”

Under the terms of the agreement, Partex will focus on identifying relevant companies across the globe that may be interested in licensing AK0707, based on its enhanced therapeutic potential. The partnership will include outreach, market analysis, and the negotiation of terms with interested parties.

“We look forward to working with Partex to help bring AK0707 to new markets and therapeutic areas,” said Dr. Haiqing Yuan, Chief Operating Officer, ArkBio]. “Their AI expertise will be invaluable in helping us realize the broader potential of this promising compound, and we are confident this collaboration will lead to new opportunities for AK0707 in the global market.”

The collaboration is expected to significantly expedite the out-licensing process, with both companies committed to ensuring that AK0707 reaches its full potential across a broad range of indications.

About Partex
Partex is a leading innovator in the field of pharmaceutical AI, specializing in AI-driven drug development and licensing strategies. The company’s proprietary platform uses advanced machine learning techniques to identify new drug candidates, predict therapeutic applications, and accelerate the out-licensing process, helping to bring novel therapies to market faster.

About Shanghai Ark Biopharmaceutical Co., Ltd.
Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) is a Chinese biopharmaceutical company focused on the development of innovative therapies for unmet medical needs. The company’s pipeline includes novel compounds for the treatment of pediatric and respiratory diseases. ArkBio is committed to advancing groundbreaking therapies that have the potential to transform patient care.

For more information or media inquiries, please contact:
Nidhi Duhan
Business Operations Manager
Partex NV
info@partex.io